Exploration of Targeted Anti-tumor Therapy, Journal Year: 2025, Volume and Issue: 6
Published: April 7, 2025
The combination of enfortumab vedotin and pembrolizumab (EVP) has been recently approved for patients with locally advanced metastatic urothelial carcinoma. This showed a higher objective response rate superior progression-free survival overall over traditional platinum-based chemotherapy in the frontline setting pivotal EV-302 trial. Despite success, subset primary refractory disease, another will develop secondary resistance time. Resistance to may include downregulation nectin-4 expression minimize antibody binding, upregulation efflux pumps against toxin, or direct by tubulin toxin. includes several methods downregulate immune system. Additionally, type histology carcinoma likely plays an important role resisting EVP. review summarizes these possible mechanisms resistance, potential biomarkers predictive overcome
Language: Английский